The multi-epitope approach for immunotherapy for cancer

Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors

Ichiro Kawashima, Stephen J. Hudson, Van Tsai, Scott Southwood, Kazutoh Takesako, Ettore Appella, Alessandro Sette, Esteban Celis

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

One approach to development of specific cancer immunotherapy relies on the induction of cytotoxic T lymphocytes (CTL) specific for tumor-associated antigens (TAA). Induction of TAA-specific CTL could be used towards the eradication of established tumors, or to prevent their dissemination or recurrence after primary treatment. The present study identifies a set of CTL epitopes from TAA frequently found on solid epithelial rumors such as breast, lung and gastro-intestinal tumors. Specifically, HLA-A2.1 binding peptides from the MAGE2, MAGE3, HER-2/neu and CEA antigens were tested for their capacity to elicit in vitro anti-tumor CTL using lymphocytes from normal volunteers and autologous dendritic cells as antigen-presenting cells. A total of 6 new epitopes (MAGE2[10157], MAGE3[9112], CEA[9691], CEA[924]. HER2[9435] and HER2[95]) were identified which were capable of specifically recognizing tumor cell lines expressing HLA-A2.1 and the corresponding TAA. In one case (CEA[924]), induction of vigorous anti- tumor CTL responses required epitope engineering to increase HLA-A2.1 binding affinity. Finally, most of the newly identified epitopes (5 out of 6) were found to be highly crossreactive with other common HLA alleles of the A2 supertype (A2.2, A2.3, A2.6 and A6802), thus demonstrating their potential in providing broad and non-ethnically biased population coverage. The results are discussed in the context of the development of multi-epitope-based therapies with broad applicability for patients suffering from commonly found tumors.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalHuman Immunology
Volume59
Issue number1
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

T-Lymphocyte Epitopes
Cytotoxic T-Lymphocytes
Neoplasm Antigens
Immunotherapy
Epitopes
Neoplasms
HLA-A2 Antigen
Antigen-Presenting Cells
Tumor Cell Line
Dendritic Cells
Healthy Volunteers
Breast
Alleles
Lymphocytes
Antigens
Recurrence
Lung
Peptides
Therapeutics
Population

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The multi-epitope approach for immunotherapy for cancer : Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. / Kawashima, Ichiro; Hudson, Stephen J.; Tsai, Van; Southwood, Scott; Takesako, Kazutoh; Appella, Ettore; Sette, Alessandro; Celis, Esteban.

In: Human Immunology, Vol. 59, No. 1, 01.01.1998, p. 1-14.

Research output: Contribution to journalArticle

Kawashima, Ichiro ; Hudson, Stephen J. ; Tsai, Van ; Southwood, Scott ; Takesako, Kazutoh ; Appella, Ettore ; Sette, Alessandro ; Celis, Esteban. / The multi-epitope approach for immunotherapy for cancer : Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. In: Human Immunology. 1998 ; Vol. 59, No. 1. pp. 1-14.
@article{c887da8462784dc7855dcc5e90d9b388,
title = "The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors",
abstract = "One approach to development of specific cancer immunotherapy relies on the induction of cytotoxic T lymphocytes (CTL) specific for tumor-associated antigens (TAA). Induction of TAA-specific CTL could be used towards the eradication of established tumors, or to prevent their dissemination or recurrence after primary treatment. The present study identifies a set of CTL epitopes from TAA frequently found on solid epithelial rumors such as breast, lung and gastro-intestinal tumors. Specifically, HLA-A2.1 binding peptides from the MAGE2, MAGE3, HER-2/neu and CEA antigens were tested for their capacity to elicit in vitro anti-tumor CTL using lymphocytes from normal volunteers and autologous dendritic cells as antigen-presenting cells. A total of 6 new epitopes (MAGE2[10157], MAGE3[9112], CEA[9691], CEA[924]. HER2[9435] and HER2[95]) were identified which were capable of specifically recognizing tumor cell lines expressing HLA-A2.1 and the corresponding TAA. In one case (CEA[924]), induction of vigorous anti- tumor CTL responses required epitope engineering to increase HLA-A2.1 binding affinity. Finally, most of the newly identified epitopes (5 out of 6) were found to be highly crossreactive with other common HLA alleles of the A2 supertype (A2.2, A2.3, A2.6 and A6802), thus demonstrating their potential in providing broad and non-ethnically biased population coverage. The results are discussed in the context of the development of multi-epitope-based therapies with broad applicability for patients suffering from commonly found tumors.",
author = "Ichiro Kawashima and Hudson, {Stephen J.} and Van Tsai and Scott Southwood and Kazutoh Takesako and Ettore Appella and Alessandro Sette and Esteban Celis",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S0198-8859(97)00255-3",
language = "English (US)",
volume = "59",
pages = "1--14",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - The multi-epitope approach for immunotherapy for cancer

T2 - Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors

AU - Kawashima, Ichiro

AU - Hudson, Stephen J.

AU - Tsai, Van

AU - Southwood, Scott

AU - Takesako, Kazutoh

AU - Appella, Ettore

AU - Sette, Alessandro

AU - Celis, Esteban

PY - 1998/1/1

Y1 - 1998/1/1

N2 - One approach to development of specific cancer immunotherapy relies on the induction of cytotoxic T lymphocytes (CTL) specific for tumor-associated antigens (TAA). Induction of TAA-specific CTL could be used towards the eradication of established tumors, or to prevent their dissemination or recurrence after primary treatment. The present study identifies a set of CTL epitopes from TAA frequently found on solid epithelial rumors such as breast, lung and gastro-intestinal tumors. Specifically, HLA-A2.1 binding peptides from the MAGE2, MAGE3, HER-2/neu and CEA antigens were tested for their capacity to elicit in vitro anti-tumor CTL using lymphocytes from normal volunteers and autologous dendritic cells as antigen-presenting cells. A total of 6 new epitopes (MAGE2[10157], MAGE3[9112], CEA[9691], CEA[924]. HER2[9435] and HER2[95]) were identified which were capable of specifically recognizing tumor cell lines expressing HLA-A2.1 and the corresponding TAA. In one case (CEA[924]), induction of vigorous anti- tumor CTL responses required epitope engineering to increase HLA-A2.1 binding affinity. Finally, most of the newly identified epitopes (5 out of 6) were found to be highly crossreactive with other common HLA alleles of the A2 supertype (A2.2, A2.3, A2.6 and A6802), thus demonstrating their potential in providing broad and non-ethnically biased population coverage. The results are discussed in the context of the development of multi-epitope-based therapies with broad applicability for patients suffering from commonly found tumors.

AB - One approach to development of specific cancer immunotherapy relies on the induction of cytotoxic T lymphocytes (CTL) specific for tumor-associated antigens (TAA). Induction of TAA-specific CTL could be used towards the eradication of established tumors, or to prevent their dissemination or recurrence after primary treatment. The present study identifies a set of CTL epitopes from TAA frequently found on solid epithelial rumors such as breast, lung and gastro-intestinal tumors. Specifically, HLA-A2.1 binding peptides from the MAGE2, MAGE3, HER-2/neu and CEA antigens were tested for their capacity to elicit in vitro anti-tumor CTL using lymphocytes from normal volunteers and autologous dendritic cells as antigen-presenting cells. A total of 6 new epitopes (MAGE2[10157], MAGE3[9112], CEA[9691], CEA[924]. HER2[9435] and HER2[95]) were identified which were capable of specifically recognizing tumor cell lines expressing HLA-A2.1 and the corresponding TAA. In one case (CEA[924]), induction of vigorous anti- tumor CTL responses required epitope engineering to increase HLA-A2.1 binding affinity. Finally, most of the newly identified epitopes (5 out of 6) were found to be highly crossreactive with other common HLA alleles of the A2 supertype (A2.2, A2.3, A2.6 and A6802), thus demonstrating their potential in providing broad and non-ethnically biased population coverage. The results are discussed in the context of the development of multi-epitope-based therapies with broad applicability for patients suffering from commonly found tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031937298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031937298&partnerID=8YFLogxK

U2 - 10.1016/S0198-8859(97)00255-3

DO - 10.1016/S0198-8859(97)00255-3

M3 - Article

VL - 59

SP - 1

EP - 14

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 1

ER -